Pacira BioSciences, Inc.PCRXNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank97
5Y CAGR+57.0%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+57.0%/yr
Long-term compound
Percentile
P97
Near historical high
vs 5Y Ago
9.5x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 44.24% |
| Q3 2025 | -7.92% |
| Q2 2025 | 11.28% |
| Q1 2025 | 6.05% |
| Q4 2024 | 25.09% |
| Q3 2024 | -6.07% |
| Q2 2024 | 11.51% |
| Q1 2024 | -6.29% |
| Q4 2023 | -6.56% |
| Q3 2023 | 10.66% |
| Q2 2023 | 9.82% |
| Q1 2023 | -2.09% |
| Q4 2022 | -9.79% |
| Q3 2022 | -26.17% |
| Q2 2022 | 21.65% |
| Q1 2022 | 39.26% |
| Q4 2021 | 34.00% |
| Q3 2021 | -7.91% |
| Q2 2021 | -20.82% |
| Q1 2021 | 3.57% |
| Q4 2020 | 4.64% |
| Q3 2020 | 7.57% |
| Q2 2020 | -13.90% |
| Q1 2020 | -19.51% |
| Q4 2019 | -2.97% |
| Q3 2019 | 13.62% |
| Q2 2019 | 23.94% |
| Q1 2019 | 1.48% |
| Q4 2018 | -4.85% |
| Q3 2018 | 21.72% |
| Q2 2018 | -14.88% |
| Q1 2018 | 43.38% |
| Q4 2017 | -14.84% |
| Q3 2017 | -37.55% |
| Q2 2017 | 13.37% |
| Q1 2017 | -2.56% |
| Q4 2016 | 74.99% |
| Q3 2016 | 4.19% |
| Q2 2016 | -1.38% |
| Q1 2016 | -27.83% |